Interview: Chris Garabedian
Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.
Best Practices in Social Listening: Life Sciences
Digital Marketing According to HIPAA
Four Perspectives That Help Build Business Advantage